2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Market Capitalization: $74.87 Billion
1-Year Performance: -28.90%
Number of Hedge Fund Holders: 68
Analyst Upside Potential: 43.11%
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops medicines to treat serious diseases. It manufactures and sells treatments for conditions like eye diseases, cancer, allergies, heart and metabolic issues, neurological disorders, infectious diseases, and other rare conditions. Its strategic edge lies in the use of advanced technologies including platforms like VelociSuite that help design fully human antibodies and innovative therapies more efficiently.
On February 25, the company received a buy rating from Canaccord Genuity’s analyst John Newman. The analyst kept his price target of $1,152 while noting that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has a strong pipeline and is making strategic advancements, particularly related to its gene therapy, DB-OTO. The investigational gene therapy has shown significant improvements in hearing for children with profound genetic deafness caused by otoferlin mutations. Moreover, Clinical trials demonstrated measurable gains in hearing through Pure Tone Audiometry (PTA) and Auditory Brainstem Response (ABR), with some children achieving near-normal hearing levels. The therapy also has a favorable safety profile, with no drug-related adverse events reported.
Beyond DB-OTO, the company’s pipeline includes programs like the Factor XI initiative, which is expected to support revenue stability amidst competitive pressures on existing products like EYLEA. It is one of the worst-performing large-cap stocks to buy according to analysts.
Amalthea Fund stated the following regarding Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2024 investor letter:
“Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – the biggest loser in the book by absolute dollars. Regeneron is a large position for us. We wrote the position up in June 2021 letter. The stock has almost doubled since the original write-up, but it is down on the month. Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way.
Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.
Eylea is a VEGF drug that is injected into patients’ eyes and stops macular degeneration (the main cause of blindness in old people). The drug stops capillaries growing in the retina…” (Click here to read the full text)
